[go: up one dir, main page]

MX2015008310A - Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. - Google Patents

Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.

Info

Publication number
MX2015008310A
MX2015008310A MX2015008310A MX2015008310A MX2015008310A MX 2015008310 A MX2015008310 A MX 2015008310A MX 2015008310 A MX2015008310 A MX 2015008310A MX 2015008310 A MX2015008310 A MX 2015008310A MX 2015008310 A MX2015008310 A MX 2015008310A
Authority
MX
Mexico
Prior art keywords
hif
treatment
related conditions
inducible factor
hypoxia inducible
Prior art date
Application number
MX2015008310A
Other languages
English (en)
Other versions
MX359029B (es
Inventor
David A Ross
Ralph Christian Crumrine
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of MX2015008310A publication Critical patent/MX2015008310A/es
Publication of MX359029B publication Critical patent/MX359029B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

La presente invención se refiere a procedimientos para el tratamiento enfermedades relacionadas con el factor inducible por hipoxia (HIF) y, en particular, a procedimientos para el tratamiento de enfermedades relacionadas con el HIF que comprenden la administración de una composición que comprende transferrinas.
MX2015008310A 2014-07-11 2015-06-25 Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. MX359029B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462023446P 2014-07-11 2014-07-11

Publications (2)

Publication Number Publication Date
MX2015008310A true MX2015008310A (es) 2016-01-11
MX359029B MX359029B (es) 2018-09-12

Family

ID=53385523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008310A MX359029B (es) 2014-07-11 2015-06-25 Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.

Country Status (25)

Country Link
US (3) US9687530B2 (es)
EP (3) EP2977056B1 (es)
JP (1) JP6517100B2 (es)
KR (3) KR102219557B1 (es)
CN (1) CN105288598A (es)
AR (1) AR101133A1 (es)
AU (3) AU2015203264B2 (es)
BR (1) BR102015015916A2 (es)
CA (3) CA3191469A1 (es)
CL (1) CL2015001936A1 (es)
ES (3) ES2988818T3 (es)
FI (1) FI3795171T3 (es)
HU (1) HUE053104T2 (es)
IL (1) IL239655B (es)
MX (1) MX359029B (es)
MY (2) MY184341A (es)
NZ (1) NZ709399A (es)
PL (2) PL2977056T3 (es)
PT (3) PT2977056T (es)
RU (1) RU2686308C2 (es)
SG (2) SG10201505207RA (es)
TR (1) TR201815058T4 (es)
TW (1) TWI704926B (es)
UY (1) UY36173A (es)
ZA (2) ZA201504705B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053104T2 (hu) * 2014-07-11 2021-06-28 Grifols Worldwide Operations Ltd Transzferrin hipoxia indukálta faktorral (HIF) kapcsolatos állapotok, például iszkémia kezelésében történõ alkalmazásra
CN107831315B (zh) * 2017-10-31 2019-11-05 中国科学院昆明动物研究所 转铁蛋白标志物及其应用
TW202216184A (zh) * 2020-07-08 2022-05-01 愛爾蘭商格里佛全球營運有限公司 具有神經再生性應用的組合物
AR122901A1 (es) * 2020-07-08 2022-10-12 Grifols Worldwide Operations Ltd Composiciones que tienen aplicaciones neuroregenerativas
RU2747653C1 (ru) * 2021-01-11 2021-05-11 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ диагностики нарушения обмена железа при тяжелых формах covid-19
EP4052723A1 (en) 2021-03-02 2022-09-07 Grifols Worldwide Operations Limited Alpha-1 antitrypsin dosing regimen
EP4311556A1 (en) 2022-07-28 2024-01-31 Grifols Worldwide Operations Limited Antithrombin in stroke

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419365A (en) * 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5986067A (en) * 1991-02-08 1999-11-16 The University Of Vermont And State Agricultural College Recombinant transferrins, transferrin half-molecules and mutants thereof
AU4553793A (en) * 1992-07-10 1994-01-31 University Of British Columbia, The Use of p97 and iron binding proteins as diagnostic and therapeutic agents
IT1278136B1 (it) * 1995-07-12 1997-11-17 Piera Valenti Associazione costituita dsa lattoferrina (o suoi analoghi) e deferossamina metalsulfonato (o altri chelanti ioni metallici) per
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6004986A (en) * 1997-05-08 1999-12-21 The University Of Virginia Patent Foundation Method for treating cerebral vasospasm and cerebral ischemia using iron chelators and pharmaceutical compositions therefor
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US20020164571A1 (en) 2001-03-02 2002-11-07 Hammerman Marc R. Method of preserving metanephroi in vitro prior to transplantation
DK1463823T3 (da) 2001-12-06 2013-06-03 Fibrogen Inc Fremgangsmåder til forhøjelse af endogent erythropoetin (epo)
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US20090215687A1 (en) * 2005-10-21 2009-08-27 Cornell Research Foundation, Inc. Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
WO2007076505A2 (en) * 2005-12-28 2007-07-05 Essential Skincare, Llc Transferrin and transferrin-based compositions for diabetes treatment
WO2007081654A2 (en) * 2005-12-28 2007-07-19 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
WO2008113134A1 (en) * 2007-03-20 2008-09-25 Garvan Institute Of Medical Research Method of transplantation of a kidney
ITLU20070009A1 (it) * 2007-05-21 2008-11-22 Kedrion Spa Uso di transferrina per la preparazione di composizioni farmaceutiche utili per il trattamento di infezioni batteriche come coadiuvanti nella terapia antibiotica.
EP2215052B1 (en) * 2007-11-01 2013-07-24 Rachel Codd Desferrioxamine conjugates, derivatives and analogues
US20120329836A1 (en) 2011-06-06 2012-12-27 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
CN106110326A (zh) 2011-10-12 2016-11-16 思佰益药业股份有限公司 移植器官的成活促进剂
PT2776058T (pt) * 2011-11-11 2016-08-24 Fundaciã³ Inst D'investigaciã³ En Ciã¿Ncies De La Salut Germans Trias I Pujol Apotransferrina para tratamento do acidente vascular cerebral
US9763899B2 (en) * 2012-08-30 2017-09-19 The Board Of Trustees Of The Leland Stanford Junior University Iron chelators and use thereof for reducing transplant failure during rejection episodes
HUE053104T2 (hu) * 2014-07-11 2021-06-28 Grifols Worldwide Operations Ltd Transzferrin hipoxia indukálta faktorral (HIF) kapcsolatos állapotok, például iszkémia kezelésében történõ alkalmazásra

Also Published As

Publication number Publication date
EP3300742B1 (en) 2020-11-04
AU2019264588B2 (en) 2021-03-25
ZA202203445B (en) 2022-09-28
SG10201505207RA (en) 2016-02-26
EP2977056B1 (en) 2018-09-12
PL3300742T3 (pl) 2021-05-04
KR102219557B1 (ko) 2021-02-24
AU2015203264A1 (en) 2016-01-28
TR201815058T4 (tr) 2018-11-21
KR102310000B1 (ko) 2021-10-07
CN105288598A (zh) 2016-02-03
IL239655B (en) 2019-07-31
RU2015126920A (ru) 2017-01-10
CL2015001936A1 (es) 2015-12-28
KR20210021339A (ko) 2021-02-25
US20160008437A1 (en) 2016-01-14
EP3795171B1 (en) 2024-04-10
ZA201504705B (en) 2022-09-28
AR101133A1 (es) 2016-11-23
FI3795171T3 (fi) 2024-05-10
KR20190132966A (ko) 2019-11-29
TWI704926B (zh) 2020-09-21
CA2894239A1 (en) 2016-01-11
NZ709399A (en) 2019-10-25
PT3795171T (pt) 2024-05-08
ES2693602T3 (es) 2018-12-12
JP2016020342A (ja) 2016-02-04
CA3191475A1 (en) 2016-01-11
EP3300742A1 (en) 2018-04-04
UY36173A (es) 2016-02-29
PL2977056T3 (pl) 2019-03-29
USRE49129E1 (en) 2022-07-12
AU2019264588A1 (en) 2019-12-05
MY205329A (en) 2024-10-16
MY184341A (en) 2021-04-01
AU2021201445B2 (en) 2024-02-29
MX359029B (es) 2018-09-12
RU2686308C2 (ru) 2019-04-25
TW201622742A (zh) 2016-07-01
EP3795171A1 (en) 2021-03-24
PT2977056T (pt) 2018-11-07
KR20160007367A (ko) 2016-01-20
US9687530B2 (en) 2017-06-27
CA3191469A1 (en) 2016-01-11
AU2021201445A1 (en) 2021-03-25
CA2894239C (en) 2023-05-09
HK1220895A1 (en) 2017-05-19
HUE053104T2 (hu) 2021-06-28
SG10201811078XA (en) 2019-01-30
BR102015015916A2 (pt) 2016-01-12
RU2015126920A3 (es) 2019-01-15
JP6517100B2 (ja) 2019-05-22
ES2988818T3 (es) 2024-11-21
PT3300742T (pt) 2021-01-25
USRE50230E1 (en) 2024-12-10
AU2015203264B2 (en) 2019-08-22
EP2977056A2 (en) 2016-01-27
NZ757595A (en) 2024-01-26
EP2977056A3 (en) 2016-04-27
ES2843783T3 (es) 2021-07-20

Similar Documents

Publication Publication Date Title
MX378145B (es) Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
PH12016501763B1 (en) Multispecific antibodies
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018500379B1 (en) Biopharmaceutical compositions
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
PH12015502832B1 (en) Processes for producing dark red and dark brown natural cocoa
MX2015016603A (es) Composiciones de corticosteroides.
CA2986376C (en) Poxvirus-derived promoter, and vector comprising same
PH12017500084A1 (en) Vitamin b2 and its use
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
PH12016502284B1 (en) Cough medicine containing ambroxol hydrochloride
MX376440B (es) Desaromatización oxidativa de berbinas.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
HUP1500583A2 (en) Multicopter for transporting people, and method to improve aerodinamic properties of the multicopter
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes

Legal Events

Date Code Title Description
FG Grant or registration